FINGOLIMOD (fingolimod HCl)
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
AUROBINDO PHARM
Drug class
Multiple Sclerosis Agents, General
The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism. Read more about Multiple Sclerosis Agents, General
115 drugs in this class 49 manufacturers
Drugs in Multiple Sclerosis Agents, General
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
AUROBINDO PHARM
DIMETHYL FUMARATE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
ASCEND LABORATO
FINGOLIMOD (fingolimod HCl)
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
ASCEND LABORATO
FINGOLIMOD (fingolimod HCl)
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
ZYDUS PHARMACEU
FINGOLIMOD (fingolimod HCl)
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
GLENMARK PHARMA
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
GLENMARK PHARMA
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
BIOCON PHARMA I
DIMETHYL FUMARATE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
SOLA PHARMACEUT
Filter & compare in the drug finder →
Opens the drug finder with Multiple Sclerosis Agents, General preselected. Add indication or manufacturer filters there.
The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism.
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies.
These agents work predominantly through immunomodulatory and immunosuppressive pathways to decrease central nervous system inflammation, reduce clinical relapse frequency, and slow disability progression.
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis.
-
ks.gov
The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism
-
cms.gov
The classification "Multiple Sclerosis Agents, General" represents a broad administrative and formulary category rather than a single pharmacologic drug class defined by a shared molecular mechanism
-
nationalmssociety.org
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies
-
nv.gov
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies
-
drugs.com
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies
-
patsnap.com
It encompasses diverse disease-modifying therapies (DMTs) and symptomatic treatments, including interferons, glatiramer acetate, sphingosine-1-phosphate receptor modulators, fumarates, and monoclonal antibodies These agents work predominantly through immunomodulatory and immunosuppressive pathways to decrease central nervous system inflammation, reduce clinical relapse frequency, and slow disability progression
-
nih.gov
These agents work predominantly through immunomodulatory and immunosuppressive pathways to decrease central nervous system inflammation, reduce clinical relapse frequency, and slow disability progression
-
fda.gov
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis
-
fda.gov
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis
-
fda.gov
Clinically, these medications are primarily indicated for treating spectrum disorders of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and progressive forms of multiple sclerosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.